<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02840708</url>
  </required_header>
  <id_info>
    <org_study_id>NTU</org_study_id>
    <nct_id>NCT02840708</nct_id>
  </id_info>
  <brief_title>SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic Study</brief_title>
  <official_title>SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Niigata University Medical &amp; Dental Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Niigata University Medical &amp; Dental Hospital</source>
  <brief_summary>
    <textblock>
      Objective: Evaluate Pharmacokinetics and determine the safety of GM-CSF single dose&#xD;
      inhalation.&#xD;
&#xD;
      Study Design: Pharmacokinetic open study&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">September 1, 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum level of Sargramostim</measure>
    <time_frame>0.5,1,2,4,8,12 and 24 hours after inhalation</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Pulmonary Alveolar Proteinosis, Autoimmune</condition>
  <arm_group>
    <arm_group_label>125mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SK-1401 125mcg single inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>250mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SK-1401 250mcg single inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>500mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SK-1401 500mcg single inhalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sargramostim</intervention_name>
    <arm_group_label>125mcg</arm_group_label>
    <arm_group_label>250mcg</arm_group_label>
    <arm_group_label>500mcg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects judged to be appropriate for the study by the attending physician&#xD;
&#xD;
          2. can provide signed informed consent.&#xD;
&#xD;
             aPAP patient must meet the following&#xD;
&#xD;
          3. aPAP patient aged over 20 and below 80 years old (as of the date of registration)&#xD;
&#xD;
          4. aPAP severity is mild or moderate. (not severe)&#xD;
&#xD;
             Healthy volunteer must meet the following&#xD;
&#xD;
          5. Japanese healthy male subject aged over 20 and below 45 years old (as of the date of&#xD;
             registration).&#xD;
&#xD;
          6. BMI (Body mass index) is between 18 and 25.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. WBC of 12,000/mcl or more&#xD;
&#xD;
          2. Fever of 38 degree celsius or more&#xD;
&#xD;
          3. History of malignant disease within recent 5 years (not applied to the treated cases&#xD;
             of local basal cell carcinoma)&#xD;
&#xD;
          4. Complication of severe cardiovascular diseases including congestive heart failure,&#xD;
             angina pectoris, hemorrhagic tendency, etc.&#xD;
&#xD;
          5. Complication of respiratory diseases such as pulmonary infectious disease(incl.&#xD;
             pulmonary tuberculosis), interstitial pneumonitis, lung fibrosis or bronchiectasis, in&#xD;
             which the evaluations of safety of GM-CSF therapy are considered to be difficult.&#xD;
&#xD;
          6. History or complication of infectious diseases which require systemic administration&#xD;
             of antibiotics, antifungal or antiviral agents within recent 2 weeks.&#xD;
&#xD;
          7. liver dysfunction&#xD;
&#xD;
          8. renal dysfunction&#xD;
&#xD;
          9. Previous experience of severe and unexplained adverse events during aerosol delivery&#xD;
             of any kind of medicinal product&#xD;
&#xD;
         10. Positive for HIV-Ab, HBs-Ag, HCV-Ab, STS or TPHA&#xD;
&#xD;
         11. allergic to GM-CSF.&#xD;
&#xD;
         12. addicted to illegal drugs&#xD;
&#xD;
         13. Participation to other clinical trials within 12 weeks before registration.&#xD;
&#xD;
         14. smoking within 5 years&#xD;
&#xD;
         15. cannot follow the procedure defined in this protocol&#xD;
&#xD;
             aPAP patient must exclude the following&#xD;
&#xD;
         16. Pregnant or possibly pregnant women, lactating women, and women who desire to become&#xD;
             pregnant during the study period&#xD;
&#xD;
         17. Patients who have been treated with whole-lung lavage, repeated segmental-lung lavage,&#xD;
             GM-CSF or rituximab within 6 months before the start of the study.&#xD;
&#xD;
         18. taking other inhalation.&#xD;
&#xD;
             Healthy volunteer must exclude the following&#xD;
&#xD;
         19. taking any medicines (incl. OTC).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Niigata University Med &amp; Dental Hospital</name>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>July 13, 2016</study_first_submitted>
  <study_first_submitted_qc>July 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2016</study_first_posted>
  <last_update_submitted>December 15, 2017</last_update_submitted>
  <last_update_submitted_qc>December 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Pulmonary Alveolar Proteinosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

